Latest Benzimidazoles Stories

The results of several studies released on Monday are suggesting that certain heartburn medicines may be doing more harm than good. Serious side effects could arise and it has been recommended that people use the drugs with caution. AstraZeneca's Nexium and Prilosec brands are among the drugs that could be harmful to health. While the drugs are helpful to the right patients, they can increase the risk of fractures in post-menopausal women and cause bacterial infections in many patients,...

NEW ORLEANS, May 5 /PRNewswire/ -- What: Data results from a recent retrospective analysis of DEXILANT delayed release capsules and lansoprazole were presented at Digestive Disease Week (DDW) 2010 in New Orleans. DEXILANT is a proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR) formulation. Takeda recently announced that the product trade name for dexlansoprazole in the United States would be changed to DEXILANT from KAPIDEX(TM) (dexlansoprazole). The medical community has...

DEERFIELD, Ill., April 26 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. today announced that DEXILANT(TM) (dexlansoprazole) delayed release capsules are now available in United States (U.S.) pharmacies. Takeda recently announced that the product trade name for dexlansoprazole in the U.S. would be changed from KAPIDEX(TM) to DEXILANT. The formulation, indication and approved dosages of DEXILANT remain the same as that of KAPIDEX, which was originally approved by the U.S. Food...

ROCKVILLE, Md., March 15 /PRNewswire-USNewswire/ -- Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a drug that prevents blood clots - were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at the National Institutes of Health. The study also...

DEERFIELD, Ill., March 4 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. announced today that KAPIDEX(TM) (dexlansoprazole) will be marketed in the United States under the new product trade name DEXILANT(TM) (dexlansoprazole). The product is indicated for heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. After receiving reports of dispensing errors between KAPIDEX...

DEERFIELD, Ill., Feb. 9 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated...

NEW YORK, Jan. 25 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, announced that it recently was advised that its Suzhou Erye Pharmaceutical subsidiary ("Erye") received approval as of November 6, 2009 from the State Food and Drug Administration (SFDA) in China to manufacture and sell omeprazole 20mg capsules. Omeprazole, a proton pump inhibitor (PPI), is...

A new study provides welcome news for patients with a common clotting disorder known as venous thromboembolism (VTE).The condition is estimated to impact 62,000 Canadians and half-a-million Americans every year, and occurs when an abnormal clot forms in a vein and restricts the flow of blood, causing pain and swelling. In some cases, the clot may detach from its point of origin and travel through the heart to the lungs, causing a potentially fatal condition known as a pulmonary...

ORLANDO, Fla., Nov. 17 /PRNewswire-USNewswire/ -- Today the FDA notified healthcare professionals of new safety information concerning a drug interaction between clopidogrel, an anti-clotting medication, and omeprazole, a proton pump inhibitor (PPI) used to reduce stomach acid. The FDA notes that they have new data showing that when healthy volunteers received clopidogrel with omeprazole, clopidogrel was less effective in its anti-clotting action than when given without omeprazole. The...

CINCINNATI, Nov. 12 /PRNewswire-FirstCall/ -- The National Football League, Prilosec OTC® and Pro-Football Hall-of-Fame Member John Madden announced today the creation of the first annual Madden Most Valuable Protectors Award presented by Prilosec OTC. The award will celebrate the important role linemen play in their team's success and honor the NFL's best offensive linemen based on their 2009 regular season performance. While most attention is typically focused on more glamorous...